VANTABIO
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
ADVISORY-Alert incorrectly tagged to Vanta Bioscience Ltd withdrawn
An alert on automated compliance and trust management platform Vanta expanding into Australia and New Zealand was incorrectly tagged to medical research company Vanta Bioscience Ltd VANB.BO and has been withdrawn.
There will be no substitute.
STORY_NUMBER:FWN3LR1EZ
STORY_DATE:15/10/2024
STORY_TIME:08:07:18 PM GMT
An alert on automated compliance and trust management platform Vanta expanding into Australia and New Zealand was incorrectly tagged to medical research company Vanta Bioscience Ltd VANB.BO and has been withdrawn.
There will be no substitute.
STORY_NUMBER:FWN3LR1EZ
STORY_DATE:15/10/2024
STORY_TIME:08:07:18 PM GMT
Sequoia Capital-backed Vanta raises funding at $2.45 bln valuation
Adds CEO comment in paragraph 6
By Pritam Biswas
July 24 (Reuters) - Online security and compliance management platform Vanta said on Wednesday it had raised $150 million in a fresh funding round led by venture capital firm Sequoia Capital, giving it a valuation of $2.45 billion.
Companies pursuing artificial intelligence (AI) adoption are attracting the attention of U.S. venture capital firms after a near two-year lull driven by high interest rates and a sluggish exit market for startup investors.
Vanta said it wants to double down on its AI innovation, eliminate legacy tools in compliance and deepen its global presence by venturing into the UK and Australia.
The venture capital businesses of banking giants Goldman Sachs GS.N and JPMorgan Chase JPM.N also participated in the round that saw all previous investors returning, bringing the lifetime raise of the company to $353 million since 2021.
San Francisco-based Vanta had raised $50 million in 2021 in a round led by Sequoia Capital, which also participated in its fundraise the year after.
"Having Sequoia triple down on Vanta, including leading both our Series A and Series C rounds is tremendous validation," CEO Christina Cacioppo said, adding that such a sustained and long-term partnership is "rare".
The company achieved a valuation of $1.6 billion when it raised $110 million in 2022.
It has more than 8,000 customers, including hiring platform SmartRecruiters and database company ZoomInfo ZI.O.
Vanta, founded in 2018 by Cacioppo, helps its clients with security monitoring and achieving compliance certifications at a faster pace through process automation.
"We're investing in Vanta because of their demonstrated platform approach, starting with automated compliance and rapidly adding new modules," said Goldman Sachs growth equity investor Mike Reilly.
Atlassian Ventures, Craft Ventures, CrowdStrike Ventures, HubSpot Ventures, Workday Ventures and Y Combinator were the other investors in the funding round.
(Reporting by Pritam Biswas in Bengaluru; Editing by Devika Syamnath)
(([email protected];))
Adds CEO comment in paragraph 6
By Pritam Biswas
July 24 (Reuters) - Online security and compliance management platform Vanta said on Wednesday it had raised $150 million in a fresh funding round led by venture capital firm Sequoia Capital, giving it a valuation of $2.45 billion.
Companies pursuing artificial intelligence (AI) adoption are attracting the attention of U.S. venture capital firms after a near two-year lull driven by high interest rates and a sluggish exit market for startup investors.
Vanta said it wants to double down on its AI innovation, eliminate legacy tools in compliance and deepen its global presence by venturing into the UK and Australia.
The venture capital businesses of banking giants Goldman Sachs GS.N and JPMorgan Chase JPM.N also participated in the round that saw all previous investors returning, bringing the lifetime raise of the company to $353 million since 2021.
San Francisco-based Vanta had raised $50 million in 2021 in a round led by Sequoia Capital, which also participated in its fundraise the year after.
"Having Sequoia triple down on Vanta, including leading both our Series A and Series C rounds is tremendous validation," CEO Christina Cacioppo said, adding that such a sustained and long-term partnership is "rare".
The company achieved a valuation of $1.6 billion when it raised $110 million in 2022.
It has more than 8,000 customers, including hiring platform SmartRecruiters and database company ZoomInfo ZI.O.
Vanta, founded in 2018 by Cacioppo, helps its clients with security monitoring and achieving compliance certifications at a faster pace through process automation.
"We're investing in Vanta because of their demonstrated platform approach, starting with automated compliance and rapidly adding new modules," said Goldman Sachs growth equity investor Mike Reilly.
Atlassian Ventures, Craft Ventures, CrowdStrike Ventures, HubSpot Ventures, Workday Ventures and Y Combinator were the other investors in the funding round.
(Reporting by Pritam Biswas in Bengaluru; Editing by Devika Syamnath)
(([email protected];))
Vanta Bioscience Gets Order Worth 5.7 Million Rupees For GLP Studies
Dec 1 (Reuters) - Vanta Bioscience Ltd VANB.BO:
GETS ORDER WORTH 5.7 MILLION RUPEES FOR GLP STUDIES
Source text for Eikon: ID:nBSE8x9c4L
Further company coverage: VANB.BO
(([email protected];;))
Dec 1 (Reuters) - Vanta Bioscience Ltd VANB.BO:
GETS ORDER WORTH 5.7 MILLION RUPEES FOR GLP STUDIES
Source text for Eikon: ID:nBSE8x9c4L
Further company coverage: VANB.BO
(([email protected];;))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Vanta Bioscience do?
Vanta Bioscience Ltd, founded in 2016, offers testing analysis service charges. They specialize in research and experimental development in natural sciences and engineering.
Who are the competitors of Vanta Bioscience?
Vanta Bioscience major competitors are MIG Media Neurons, Suvidha Infraestate, Varanium Cloud, FGP, Sterling Internl.Ent, UTL Industries, Swagtam Tradg.&Serv. Market Cap of Vanta Bioscience is ₹19 Crs. While the median market cap of its peers are ₹12 Crs.
Is Vanta Bioscience financially stable compared to its competitors?
Vanta Bioscience seems to be less financially stable compared to its competitors. Altman Z score of Vanta Bioscience is 0.22 and is ranked 6 out of its 8 competitors.
Does Vanta Bioscience pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Vanta Bioscience latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Vanta Bioscience allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Inventory, Accounts Receivable, Short Term Loans & Advances
How strong is Vanta Bioscience balance sheet?
Vanta Bioscience balance sheet is weak and might have solvency issues
Is the profitablity of Vanta Bioscience improving?
The profit is oscillating. The profit of Vanta Bioscience is -₹10.46 Crs for TTM, -₹2.32 Crs for Mar 2024 and -₹6.48 Crs for Mar 2023.
Is the debt of Vanta Bioscience increasing or decreasing?
Yes, The net debt of Vanta Bioscience is increasing. Latest net debt of Vanta Bioscience is ₹65.66 Crs as of Sep-24. This is greater than Mar-24 when it was ₹60.95 Crs.
Is Vanta Bioscience stock expensive?
Vanta Bioscience is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE. Latest PE of Vanta Bioscience is 0.0, while 3 year average PE is 177. Also latest EV/EBITDA of Vanta Bioscience is 91.03 while 3yr average is 33.35.
Has the share price of Vanta Bioscience grown faster than its competition?
Vanta Bioscience has given lower returns compared to its competitors. Vanta Bioscience has grown at ~-38.8% over the last 3yrs while peers have grown at a median rate of -0.85%
Is the promoter bullish about Vanta Bioscience?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Vanta Bioscience is 69.36% and last quarter promoter holding is 69.36%.
Are mutual funds buying/selling Vanta Bioscience?
There is Insufficient data to gauge this.